Terrain Life Science and Tile Advance a Strategic Partnership in AI-Powered Precision Medicine

Newton, MA – September 16, 2025 – Terrain Life Science, Inc., a company pioneering a proprietary spatial proteomics platform, and TileBio, a leader in developing self-learning AI foundation models for digital pathology, today announced a collaboration to unite Terrain's hyperplex immunofluorescence spatial proteomics with TileBio's novel H&E and multiplex immunofluorescence algorithms to create a powerful, differentiated offering for biomarker discovery and diagnostic development.

This partnership will bring together two cutting-edge technologies to address a critical challenge in healthcare: delivering the right novel class of drug to the right patient. Terrain’s platform combines spatial proteomics with AI to map actionable drug targets from a single biopsy. Tile has developed a groundbreaking, self-learning AI that creates a proprietary visual language of cancer from both H&E-stained and multiplex immunofluorescence slides, solving critical bottlenecks in pathology diagnosis and interpretation. The synergy of these platforms has the potential to revolutionize the landscape of precision medicine by specifically aligning an individual patient's disease against novel generations of drugs.

Visionary Leadership Teams Driving Innovation
Terrain is led by a founding team with unmatched expertise in spatial biology, AI applications, and large-scale data platforms for life sciences. CEO Jay Lee, MD, PhD is a pioneering scientist and the inventor of foundational spatial biology technologies such as FISSEQ (fluorescent in situ sequencing). His groundbreaking work spans clinical medicine, genomics, and spatial proteomics. CSO Brian P. Dranka, PhD is a seasoned strategic leader with expertise in translating complex biological technologies into market-defining solutions across large-scale ‘omics and clinical data products. CTO Kirby Bloom is a technology visionary with deep experience architecting large-scale data analytics platforms across health care and life sciences.
TileBio is led by a multi-disciplinary team of researchers from the University of Glasgow who unite deep clinical expertise with advanced AI for digital pathology. CEO Christopher Walsh, PhD is an AI expert in developing self-supervised deep learning models for histopathological images without manual annotations. Professor David Chang, MD, PhD, FRCS is a renowned surgeon-scientist who brings deep clinical experience to the challenge of precision oncology therapeutic development. Professor John Le Quesne, MBBs PhD FRCPath is a leading expert in quantitative pathology and AI-driven cancer biology and biomarker discovery. CSO Ke Yuan, PhD is a specialist in computational pathology, integrating insights from imaging and sequencing to drive translational research.

Transforming Drug Discovery
"This partnership with TileBio is incredibly enabling for Terrain," said Brian Dranka PhD, Chief Strategy Officer & Co-founder of Terrain Life Science. "Enriching our hyperplex immunofluorescence data with annotations from TileBio’s foundation models could dramatically accelerate the development of next-generation diagnostics and revolutionize patient care. By integrating TileBio’s AI with our rich proteomic data, we can create a uniquely powerful approach to understanding and treating complex diseases."

"This collaboration is a testament to our shared vision of leveraging technology to improve patient outcomes well beyond our previous abilities" said Christopher Walsh, PhD, CEO of TileBio. "The integration of Terrain's spatial proteomics with our AI has the potential to create an unprecedentedly powerful tool for biomarker discovery and companion diagnostic development. We look forward to exploring this opportunity further to benefit patients with cancer in this exciting but challenging era of multiple novel classes of therapeutics."
Terrain and TileBio share a common vision: to revolutionize cancer care by ensuring that every patient receives the best possible treatment at the right time of their journey. This partnership represents a significant step towards creating a future where precision medicine is not just a goal, but a reality for every patient.

To learn more about how Terrain Life Science and Tile are shaping the future of precision medicine, please visit our websites at https://www.terrainlifescience.com and https://tilebio.com.